The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
O'BrienS.M., LamannaN., KippsT.J.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood.2015; 126(25): 2686–2694.
2.
FurmanR.R., SharmanJ.P., CoutreS.E.Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med.2014; 370(11): 997–1007.
SehnL., DonaldsonJ., FilewichA.Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood.2007; 109(10): 4171–4173.
6.
ZahraniA., IbrahimN., EidA.Case report: Rapid infusion rituximab changing practice for patient care. J Oncol Pharm.2009; 15(3): 183–186.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
Idelalisib [package insert].Foster City, CA: Gilead Sciences, Inc.; 2014.
13.
JinF., RobesonM., ZhouH.The pharmacokinetics and safety of idealalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol.2015; 55(8): 944–952.
14.
JinF., RobesonM., ZhouH.The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Cancer Chemother Pharmacol.2015; 76(6): 1133–1141.
